In today’s briefing:
- Quiddity Leaderboard-ASX Jun 23: OZ Minerals Replacements and Other Changes
- Neuren Pharmaceuticals (NEU AU): It’s Not Too Late to Join the Bandwagon; More Stream Is Still Left
- AmerisourceBergen Corporation: Detailed Credit Analysis & Financial Strength Evaluation Report
- DaVita Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report
Quiddity Leaderboard-ASX Jun 23: OZ Minerals Replacements and Other Changes
- In this insight, we take a look at the potential index changes for ASX 200, 100, 50, and 20 in the run up to the June 2023 Rebalance.
- OZ Minerals Ltd (OZL AU) upcoming deletion in April 2023 could cause a couple of intra-review replacements.
- Separately, there could be one more change in the ASX 200 index in the June 2023 review.
Neuren Pharmaceuticals (NEU AU): It’s Not Too Late to Join the Bandwagon; More Stream Is Still Left
- Neuren Pharmaceuticals (NEU AU)‘s lead product Daybue (trofinetide) has obtained FDA approval for the treatment of Rett syndrome in adult and pediatric patients two years of age and older.
- Daybue is expected to be available in the US in April, 2023. Neuren is eligible to receive royalties on net sales of trofinetide in North America, plus milestone payments.
- Geography expansion of trofinetide (mainly European approval and launch), label expansion possibility of trofinetide, and Neuren’s pipeline progress can act as potential upside catalysts for the stock.
AmerisourceBergen Corporation: Detailed Credit Analysis & Financial Strength Evaluation Report
- AmerisourceBergen is a major pharmaceutical sourcing and distribution services provider in the U.S.
- The company has reasonably strong financials and a dominant position in an oligopolistic market.
- The management believes that the acquisition of PharmaLex will help the company assist pharma and biotech companies.
DaVita Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report
- DaVita is a well-known healthcare provider within the kidney care space.
- The company entered 2023 with below par revenues though its margin profile continues to be strong.
- Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
